613 related articles for article (PubMed ID: 28445298)
61. The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients?
Kim KM; Sinn DH; Jung SH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
Liver Int; 2016 Oct; 36(10):1490-7. PubMed ID: 26936471
[TBL] [Abstract][Full Text] [Related]
62. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
[TBL] [Abstract][Full Text] [Related]
63. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
[TBL] [Abstract][Full Text] [Related]
64. Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Ye HH; Ye JZ; Xie ZB; Peng YC; Chen J; Ma L; Bai T; Chen JZ; Lu Z; Qin HG; Xiang BD; Li LQ
World J Gastroenterol; 2016 Apr; 22(13):3632-43. PubMed ID: 27053855
[TBL] [Abstract][Full Text] [Related]
65. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
66. Survival outcomes of hepatectomy for stage B Hepatocellular carcinoma in the BCLC classification.
Kamiyama T; Orimo T; Wakayama K; Shimada S; Nagatsu A; Yokoo H; Kamachi H; Yamashita K; Shimamura T; Taketomi A
World J Surg Oncol; 2017 Aug; 15(1):156. PubMed ID: 28830473
[TBL] [Abstract][Full Text] [Related]
67. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
Han K; Kim JH; Ko GY; Gwon DI; Sung KB
World J Gastroenterol; 2016 Jan; 22(1):407-16. PubMed ID: 26755886
[TBL] [Abstract][Full Text] [Related]
68. Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
Arizumi T; Ueshima K; Iwanishi M; Minami T; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ida H; Sakurai T; Kitano M; Nishida N; Kudo M
Dig Dis; 2016; 34(6):671-678. PubMed ID: 27750236
[TBL] [Abstract][Full Text] [Related]
69. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
70. Treatment of intermediate-stage hepatocellular carcinoma.
Forner A; Gilabert M; Bruix J; Raoul JL
Nat Rev Clin Oncol; 2014 Sep; 11(9):525-35. PubMed ID: 25091611
[TBL] [Abstract][Full Text] [Related]
71. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma.
Yau T; Tang VY; Yao TJ; Fan ST; Lo CM; Poon RT
Gastroenterology; 2014 Jun; 146(7):1691-700.e3. PubMed ID: 24583061
[TBL] [Abstract][Full Text] [Related]
72. Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts.
Schellhaas B; Strobel D; Stumpf M; Ganslmayer M; Pfeifer L; Goertz RS; Neurath MF; Zopf S
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1422-1427. PubMed ID: 30052538
[TBL] [Abstract][Full Text] [Related]
73. Prognosis of Early-Stage Hepatocellular Carcinoma: The Clinical Implications of Substages of Barcelona Clinic Liver Cancer System Based on a Cohort of 1265 Patients.
Kao WY; Chao Y; Chang CC; Li CP; Su CW; Huo TI; Huang YH; Chang YJ; Lin HC; Wu JC
Medicine (Baltimore); 2015 Oct; 94(43):e1929. PubMed ID: 26512620
[TBL] [Abstract][Full Text] [Related]
74. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma.
Giannini EG; Moscatelli A; Pellegatta G; Vitale A; Farinati F; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Baroni GS; Virdone R; Masotto A; Trevisani F; ;
Am J Gastroenterol; 2016 Jan; 111(1):70-7. PubMed ID: 26729544
[TBL] [Abstract][Full Text] [Related]
75. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Liu F; Meng Z; Shao G; Wang J; Wang Z; Yang J; Yip CS; He D
Mol Biol Rep; 2017 Feb; 44(1):149-158. PubMed ID: 27981445
[TBL] [Abstract][Full Text] [Related]
76. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
77. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma.
Wada H; Eguchi H; Noda T; Ogawa H; Yamada D; Tomimaru Y; Tomokuni A; Asaoka T; Kawamoto K; Gotoh K; Marubashi S; Umeshita K; Nagano H; Doki Y; Mori M
Surgery; 2016 Nov; 160(5):1227-1235. PubMed ID: 27395761
[TBL] [Abstract][Full Text] [Related]
78. Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases.
Aziz AO; Omran D; Nabeel MM; Elbaz TM; Abdelmaksoud AH; Attar IE; Shousha HI
Asian Pac J Cancer Prev; 2016; 17(5):2539-43. PubMed ID: 27268626
[TBL] [Abstract][Full Text] [Related]
79. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
[TBL] [Abstract][Full Text] [Related]
80. Treatment of hepatocellular carcinoma: beyond international guidelines.
Colombo M; Sangiovanni A
Liver Int; 2015 Jan; 35 Suppl 1():129-38. PubMed ID: 25529098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
